Cesarone M R, Laurora G, De Sanctis M T, Pomante P, Belcaro G
Clinica Cardiovascolare, Università G. D'Annunzio, Chieti.
Minerva Cardioangiol. 1992 Jan-Feb;40(1-2):15-21.
Non-invasive arterial ultrasonic biopsy (UB) has been used to evaluate and follow-up arterial wall changes in four years in asymptomatic subjects, hyperlipidemics and diabetics. Both groups of patients were randomised in a treatment group (bezafibrate 400 mg daily) and in a control group. The rate of progression (ROP) into the next higher UB class was recorded by UB scans repeated every six months. In diabetics and hyperlipidemics the rate of progression (ROP, namely the percent of patients progressing to the next class) was significantly higher than the ROP in the asymptomatic subjects. However in the bezafibrate group the ROP was significantly lower than that observed in the controls. As each UB class corresponds to different levels of risks of occult coronary ischemia and cardiovascular events in the following four years, the reduction of ROP with bezafibrate was an important and positive achievement.
无创动脉超声活检（UB）已被用于对无症状受试者、高脂血症患者和糖尿病患者的动脉壁变化进行为期四年的评估和随访。两组患者均被随机分为治疗组（每日服用400毫克苯扎贝特）和对照组。通过每六个月重复进行的UB扫描记录进展到下一个更高UB类别的进展率（ROP）。在糖尿病患者和高脂血症患者中，进展率（ROP，即进展到下一级别的患者百分比）显著高于无症状受试者。然而，在苯扎贝特组中，ROP显著低于对照组。由于每个UB类别对应于接下来四年中隐匿性冠状动脉缺血和心血管事件的不同风险水平，苯扎贝特使ROP降低是一项重要且积极的成果。
